RXi Pharmaceuticals Corporation (NASDAQ:RXII):
RXi Pharmaceuticals to Webcast Third Quarter 2017 Financial Results on Wednesday, November 8, 2017.
In the market the company is trading up by 0.93% percent from yesterday’s close.
RXi Pharmaceuticals Corporation, launched on October 8, 2011, is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Business’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator. Its clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. In addition to these clinical programs, it has a pipeline of discovery and preclinical product candidates in its therapeutic areas, as well as in other areas of interest. Its pipeline is focused on approximately three areas, including dermatology, ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing, enhancing or suppressing an immune response..
Company shares are trading at $0.55 a tad higher than $0.53, the stock’s 50 day moving average and marginally under the 200 day moving average of $0.58. The 50 day moving average moved up $0.02 and the 200 day average was down $-0.04.
Investors are more bearish on the company lately if you evaluate the rise in short interest. The firm realized a rise in short interest between September 29, 2017 and October 13, 2017 of 0.37%. Short shares grew 6,906 over that period. Days to cover decreased from 5.0 to 3.0 and the percentage of shorted shares is 0.28% as of October 13.